Handelsbanken Fonder’s Inari Medical, Inc. Common Stock NARI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-17,300
Closed -$883K 1551
2024
Q4
$883K Buy
17,300
+1,300
+8% +$63.9K ﹤0.01% 1027
2024
Q3
$660K Buy
16,000
+2,900
+22% +$139K ﹤0.01% 1119
2024
Q2
$631K Buy
13,100
+3,300
+34% +$146K ﹤0.01% 1053
2024
Q1
$470K Hold
9,800
﹤0.01% 1192
2023
Q4
$636K Buy
9,800
+2,300
+31% +$138K ﹤0.01% 1019
2023
Q3
$490K Hold
7,500
﹤0.01% 1061
2023
Q2
$436K Buy
7,500
+400
+6% +$25.2K ﹤0.01% 1147
2023
Q1
$438K Hold
7,100
﹤0.01% 1070
2022
Q4
$451K Buy
7,100
+100
+1% +$7.25K ﹤0.01% 1014
2022
Q3
$508K Hold
7,000
﹤0.01% 958
2022
Q2
$476K Buy
7,000
+1,100
+19% +$79.1K ﹤0.01% 1055
2022
Q1
$535K Hold
5,900
﹤0.01% 1158
2021
Q4
$538K Hold
5,900
﹤0.01% 1295
2021
Q3
$478K Hold
5,900
﹤0.01% 1385
2021
Q2
$550K Buy
5,900
+3,400
+136% +$330K ﹤0.01% 1310
2021
Q1
$268K Hold
2,500
﹤0.01% 1480
2020
Q4
$218K Buy
+2,500
New +$177K ﹤0.01% 1500

Other funds holding NARI

Handelsbanken Fonder's NARI Position: Q1 2025 in Review

Handelsbanken Fonder sold out of Inari Medical, Inc. Common Stock (NARI) in Q1 2025, closing a stake of 17,300 shares — an estimated $883K sold.

Handelsbanken Fonder first reported a position in NARI in Q4 2020 and held it in 17 quarters. The position peaked at $883K in Q4 2024. 4 funds tracked by Wall St. Rank hold NARI as of Q1 2025.

  • Handelsbanken Fonder reported no remaining Inari Medical, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Handelsbanken Fonder sold 17,300 Inari Medical, Inc. Common Stock shares in Q1 2025, an estimated $883K.
  • Handelsbanken Fonder first reported a position in Inari Medical, Inc. Common Stock in Q4 2020 and held it in 17 quarters.
  • Handelsbanken Fonder's Inari Medical, Inc. Common Stock position peaked at $883K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Inari Medical, Inc. Common Stock as of Q1 2025.

Based on Handelsbanken Fonder's 13F filing for Q1 2025, filed 15 Apr 2025.